Vermox
(Mebendazole)ApprovedSmall molecule
Mebendazole is used to treat infections caused by parasitic worms, such as roundworms, hookworms, and whipworms. It works by killing the worms and is commonly used in both children and adults.[2] Vermox is currently approved and in use across 12 indications[4].[1]
Vermox is one of 272 small molecule programs targeting Glioma. It is currently in Approved.
12
Indications
21
Total Trials
4
Active Trials
271
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 11 indications
Competition
Competitive Landscape
949 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1Vermox
WWim Janssens
Approved
Eylea
RegeneronPreclinical
Emend IV
Merck & Co.Preclinical
PORTRAZZA
Eli LillyPreclinical
Vascepa
AAmarin Pharma Inc.
Preclinical
Gas-X
PPortuguese Oncology Institute, Coimbra
Preclinical
Ketalar
AAultman Health Foundation
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Efficacy and Safety5 trials
Hookworm Infection2 trials
Glioma2 trials
Pediatric Brain Tumor1 trial
Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT02644291·16 enrolled
10 more indications
Growth1 trial
Hepatocellular Carcinoma1 trial
Infections1 trial
Helminthiasis1 trial
Treatment1 trial
Children1 trial
A Safety Study of Mebendazole in Children 2 to 10 Years of Age
Completed·
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT01173562·397 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT01173562·397 enrolledRegulatory
FDA Approval Timeline[5]
Jan 1, 1982
VERMOX
NDA NDA017481
Oct 19, 2016
VERMOX
NDA NDA208398
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Vermox drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Mebendazole. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Tubulin Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- WWim Janssens